Immunome (IMNM) Net Cash Flow Growth (3y) (2022 - 2026)

Immunome (IMNM) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -50.33%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.47%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -29.82%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Immunome 2.49 Bn 1.91 Bn - -70.28%

Historic Data

Download Data
DateValue
Mar 31, 2026 -70.28%
Dec 31, 2025 287.93%
Sep 30, 2025 166.87%
Jun 30, 2025 -139.90%
Mar 31, 2025 171.41%
Dec 31, 2024 -20.32%
Sep 30, 2024 -39.64%
Jun 30, 2024 -85.97%
Mar 31, 2024 270.87%
Dec 31, 2023 -37.56%
Sep 30, 2023 167.55%
Jun 30, 2023 -39.33%
Mar 31, 2023 175.47%
Dec 31, 2022 -79.55%